75659-08-4

Basic information

• Product Name: DILEVALOL HYDROCHLORIDE
• Synonyms: DILEVALOL HYDROCHLORIDE;(R,R)-Dilevalol HCL;(R,R)-Labetalol Hydrochloride
• CAS NO: 75659-08-4
• Molecular Formula: C₁₉H₂₄N₂O₃*ClH
• Molecular Weight: 364.87
• Product Categories: Pharmaceutical Raw Materials
• Mol File: 75659-08-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 192-193.5 °C (decomp)
• Boiling Point: 552.7°C at 760 mmHg
• Flash Point: 288.1°C
• Appearance: /
• Vapor Pressure: 4.75E-13mmHg at 25°C
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated)
• Stability: Hygroscopic
• CAS DataBase Reference: DILEVALOL HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DILEVALOL HYDROCHLORIDE(75659-08-4)
• EPA Substance Registry System: DILEVALOL HYDROCHLORIDE(75659-08-4)

Safety Data

• Hazardous Substances Data: 75659-08-4(Hazardous Substances Data)

Usage

Description

DILEVALOL HYDROCHLORIDE, a pharmaceutical compound, is a beta-adrenergic receptor antagonist with antihypertensive properties. It functions as an anti-adrenergic agent, specifically targeting both αand β-receptor sites, making it effective in managing high blood pressure.

Uses

Used in Pharmaceutical Industry:
DILEVALOL HYDROCHLORIDE is used as an antihypertensive agent for the treatment of high blood pressure. It works by blocking the effects of adrenaline on the heart and blood vessels, leading to a decrease in heart rate and blood pressure.
Used in Cardiovascular Applications:
DILEVALOL HYDROCHLORIDE is used as a beta-blocker for managing cardiovascular conditions such as angina, arrhythmias, and heart failure. Its ability to block both αand β-adrenergic receptors contributes to its effectiveness in treating these conditions.
Used in Research and Development:
DILEVALOL HYDROCHLORIDE is also utilized in the research and development of new pharmaceuticals targeting adrenergic receptors. Its unique properties make it a valuable tool for studying the mechanisms of adrenergic receptor interactions and developing novel treatments for various conditions.

InChI:InChI=1/C19H24N2O3.ClH/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24;/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24);1H/t13-,18+;/m1./s1

Upstream product

• 73866-23-6 5-(2-bromoacetyl)-2-hydroxybenzamide 
• 75659-06-2 (+)-(R)-α-methyl-N-(phenylmethyl)benzenepropanamine 
• 22374-89-6 (RS)-1-methyl-3-phenylpropylamine 
• 75615-54-2 5-<(R)-1-hydroxy-2-<<(R)-1-methyl-3-phenylpropyl>(phenylmethyl)amino>ethyl>-2-(phenylmethoxy)benzamide hydrochloride 

Downstream Products

• 1391051-99-2 C₁₉H₂₃NO₄ 
• 83167-32-2 (S,R)-labetalol 
• 264232-40-8 2-Hydroxy-5-[1-hydroxy-2-((R)-1-methyl-3-phenyl-propylamino)-ethyl]-benzamide 

Relevant articles and documents

Resolution of racemic amines via lipase-catalyzed benzoylation: Chemoenzymatic synthesis of the pharmacologically active isomers of labetalol

Lipase-catalyzed benzoylation of amines was shown to be feasible, in some cases with high enantioselectivity, and the best results were obtained using immobilized lipase from Candida antarctica (Novozym 435) and methyl benzoate as acyl donor in the presence of molecular sieves. The procedure was optimized for the resolution of (±)-1-methyl-3-phenylpropylamine, a key intermediate in the synthesis of antihypertensive drug labetalol, and the enantiopure (R)-benzamide was then converted into the pharmacologically active isomers of the drug. In comparison with the reported synthesis of chiral isomers of labetalol, this chemoenzymatic route offers the advantage in the lack of any chiral stoichiometric auxiliary.